Who holds it, who is betting against it, and where the big money is moving
Net of large-order buying minus selling, in USD. Over this window: −$2.42M (8 inflow days, 12 outflow days).
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 35.3% of shares outstanding.
Reported short interest has fallen from 18.07% to 17.34% of float over the last 6 biweekly reports (30 Jun 2026 to 15 Sep 2026).
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Redmile Group, LLC | Hedge Fund | 2026/Q3 | +2,679,019 | 7.7% |
| FMR | Mutual Fund | 2026/Q3 | +8,881,850 | 10.3% |
| Woodline Partners LP | Hedge Fund | 2026/Q3 | +4,587,930 | 3.7% |
| MPM BioImpact LLC | VC/PE Fund | 2026/Q3 | +3,544,354 | 1.9% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +2,905,066 | 5.2% |
| BlackRock | Mutual Fund | 2026/Q3 | +2,601,235 | 7.1% |
| The Goldman Sachs Group, Inc. | Public Company | 2026/Q3 | +1,912,568 | 1.7% |
| Goldman Sachs Asset Management, L.P. | Mutual Fund | 2026/Q3 | +1,760,131 | 1.4% |
| Logos Global Management, L.P. | Hedge Fund | 2026/Q3 | +1,500,000 | 0.8% |
| Candriam, Société En Commandite Par Actions | Mutual Fund | 2026/Q3 | +1,195,142 | 0.6% |
| MAK Capital One, LLC | Hedge Fund | 2026/Q3 | +1,138,137 | 3.1% |
| Vanguard Capital Management, LLC | Mutual Fund | 2026/Q3 | +1,131,324 | 4.2% |
| Great Point Partners, LLC | VC/PE Fund | 2026/Q3 | +1,000,000 | 1.8% |
| PanAgora Asset Management, Inc. | Mutual Fund | 2026/Q3 | +967,926 | 0.5% |
| Vanguard Portfolio Management, LLC | Mutual Fund | 2026/Q3 | +763,710 | 1.2% |
Institutional buy/sell activity by reporting period, largest moves first.
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 23 Sep 2026 | Douglas Love | Chief Executive Officer | Open Market Acquisition | +26,065 | $3.83 | 390,476 |
| 12 Aug 2026 | Thomas Wiggans | Independent Chairperson | Intent to Sell (Form 144) | -2,000 | $5.30 | – |
| 9 Aug 2026 | Mark Blumenkranz | Director | Other Derivative Acquisition | +175,000 | $5.39 | 175,000 |
| 14 Jul 2026 | Thomas Wiggans | Independent Chairperson | Intent to Sell (Form 144) | -2,000 | $6.32 | – |
| 13 Jul 2026 | Thomas Wiggans | Independent Chairperson | Intent to Sell (Form 144) | -1,000 | $5.61 | – |
| 10 Jun 2026 | Muneer Satter | Independent Director | Other Derivative Acquisition | +65,000 | $4.70 | 65,000 |
| 10 Jun 2026 | Jung Choi | Independent Director | Other Derivative Acquisition | +65,000 | $4.70 | 65,000 |
| 10 Jun 2026 | William Waddill | Independent Director | Other Derivative Acquisition | +65,000 | $4.70 | 65,000 |
| 10 Jun 2026 | Ted Yednock | Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board | Derivative Exercise and Retained | +30,646 | $1.85 | 184,807 |
| 10 Jun 2026 | William Jones | Director | Other Derivative Acquisition | +65,000 | $4.70 | 65,000 |
| 10 Jun 2026 | William Carson | Independent Director | Other Derivative Acquisition | +65,000 | $4.70 | 65,000 |
| 10 Jun 2026 | Bettina Cockroft | Independent Director | Other Derivative Acquisition | +65,000 | $4.70 | 65,000 |
| 27 May 2026 | Alerce Investment Management L.P. | Open Market Acquisition | +613,497 | $5.41 | 9,534,894 | |
| 10 May 2026 | William Carson | Independent Director | Automatic Acquisition | +8,000 | $5.78 | 78,405 |
| 9 Apr 2026 | William Carson | Independent Director | Automatic Acquisition | +8,000 | $6.20 | 70,405 |
| 9 Mar 2026 | William Carson | Independent Director | Automatic Acquisition | +8,000 | $5.67 | 62,405 |
| 1 Mar 2026 | Dean Artis | Chief Scientific Officer & Executive VP | Open Market Disposition | -5,894 | $5.43 | 74,618 |
| 1 Mar 2026 | Ted Yednock | Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board | Open Market Disposition | -5,566 | $5.42 | 154,161 |
| 1 Mar 2026 | Jennifer Lew | Chief Financial Officer | Open Market Disposition | -5,565 | $5.42 | 65,225 |
| 1 Mar 2026 | Jamie Dananberg | Chief Medical Officer | Open Market Disposition | -5,820 | $5.43 | 24,357 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 15 Sep 2026 | 32,871,995 | 17.3% | 11.7 |
| 31 Aug 2026 | 32,094,286 | 16.9% | 12.7 |
| 14 Aug 2026 | 32,583,299 | 17.2% | 13.2 |
| 31 Jul 2026 | 30,772,146 | 18.8% | 10.5 |
| 15 Jul 2026 | 29,827,889 | 18.2% | 5.7 |
| 30 Jun 2026 | 29,604,763 | 18.1% | 5.4 |
No comments yet — be the first to weigh in on ANNX.